BEFIZAL L.P. 400 mg, extended-release coated tablet 90 tablets
Active ingredients: Bezafibrate
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Extended-release coated tablet90 tabletsorale
Supply resumed · Supply disruption
Package details
Original BDPM fields are shown in French.
- Official name
- BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée
- Pharmaceutical form
- comprimé enrobé à libération prolongée
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC-Aluminium de 90 comprimé(s)
- Marketing authorisation holder
- ARROW GENERIQUES
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 22 Sept 2006
- Prescription and dispensing conditions
- Prescription only
- List II: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
62119207CIP73717738CIP133400937177382Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| BÉZAFIBRATEcomprimé | 400 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Other packages of this medicine
The same medicine in another pack size, according to BDPM.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.